# Ibrutinib and Rituxan for Chronic GVHD

> **NCT04235036** · PHASE2 · TERMINATED · sponsor: **Northside Hospital, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Graft Vs Host Disease

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT04235036
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-16
- **Primary completion:** 2022-12-23
- **Final completion:** 2022-12-23
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Low Recruitment
- **Last updated:** 2024-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04235036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04235036, "Ibrutinib and Rituxan for Chronic GVHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04235036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*